Veozah (Fezolinetant) and Nutrition: What to Eat for Best Outcomes

What You Actually Need to Know First

Veozah is a once-daily 45 mg tablet that works by blocking neurokinin 3 (NK3) receptors in the hypothalamus. In the SKYLIGHT 1 and SKYLIGHT 2 trials, fezolinetant reduced moderate-to-severe hot flash frequency by roughly 60 percent compared with about 45 percent for placebo at week 12, with sustained benefit through 52 weeks. It is the first non-hormonal, non-SSRI, non-SNRI option FDA-approved specifically for vasomotor symptoms (VMS), which affects an estimated 75 percent of menopausal women.

Unlike hormone therapy, fezolinetant does not alter estrogen, progesterone, or FSH. That distinction matters for nutrition because the drug is metabolized primarily through CYP1A2, an enzyme that many common foods and supplements either inhibit or induce. Getting this wrong can push fezolinetant plasma levels too high or, less commonly, too low.

The other nutritional priority is your liver. The prescribing information carries a warning about hepatotoxicity: in clinical trials, drug-induced liver injury occurred in a small number of patients, and the FDA requires liver enzyme testing at baseline, 3 months, and 6 months. Every dietary decision that adds stress to your liver, such as heavy alcohol use, high fructose intake, or excess saturated fat, works against you while you are on this medication.

How Fezolinetant Is Metabolized and Why Food Matters

CYP1A2: the enzyme at the center of every food interaction

Fezolinetant is a CYP1A2 substrate. When something inhibits CYP1A2, fezolinetant is broken down more slowly and its plasma concentration rises, which could increase both efficacy and side-effect risk. When something induces CYP1A2, the drug is cleared faster and may work less well.

Strong CYP1A2 inhibitors that you might consume include:

• Fluvoxamine (a prescription drug, not a food, but relevant if you take it)
• Large amounts of grapefruit juice (less potent on CYP1A2 than on CYP3A4, but still worth limiting if drinking more than 8 oz daily)
• Cruciferous vegetables cooked in very large quantities (mild CYP1A2 induction rather than inhibition, meaning they could slightly lower fezolinetant levels)
• High-dose curcumin supplements (evidence in humans is modest, but mechanistic data suggest CYP1A2 inhibition at doses above 500 mg per day)

The FDA label explicitly contraindicates fezolinetant with strong CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin. Food sources of CYP1A2 modulation are far weaker, but they are worth being consistent about, particularly if you are near the upper range of clinical response.

Charcoal-grilled meat and heterocyclic amines

Heavily charred or barbecued meat contains heterocyclic amines, which are potent CYP1A2 inducers in regular consumers. A diet heavy in well-done, charbroiled meat eaten multiple times a week has been shown to induce CYP1A2 activity by up to 30 percent in some studies. If you eat this way consistently, fezolinetant clearance could increase and reduce the drug's effectiveness.

Caffeine: a useful marker of your CYP1A2 activity

Caffeine is also metabolized by CYP1A2. If you drink three cups of coffee and feel wired all afternoon, your CYP1A2 may be naturally slow, meaning fezolinetant may accumulate more in your body. If caffeine runs through you quickly, you likely have faster CYP1A2 activity. This is not a substitute for blood monitoring, but it is a practical self-signal. Keep caffeine intake consistent day to day rather than varying wildly, because inconsistency makes it harder for your clinician to interpret any side-effect patterns.

Separately, caffeine itself is a mild hot flash trigger in some women, documented in observational menopause research. A large SWAN cohort analysis found that caffeine use was associated with worse VMS in perimenopausal women but, interestingly, lower VMS in postmenopausal women. If you are in perimenopause and still taking Veozah off-label, limiting caffeine to one to two cups before noon may reduce the background trigger burden.

Alcohol and Veozah: A Specific Warning

Why alcohol is a particular concern on fezolinetant

Alcohol deserves its own section because it sits at the intersection of two problems: it stresses the liver, and it triggers vasomotor symptoms directly. The FDA prescribing information for fezolinetant does not set a hard limit on alcohol, but the hepatotoxicity warning makes clinical guidance clear: during the first six months of treatment, while liver enzymes are being actively monitored, heavy alcohol use is contraindicated in practice even if not in letter.

The Menopause Society (formerly NAMS) states in its 2023 position statement on nonhormone therapies that lifestyle modification, including alcohol reduction, should accompany any pharmacologic VMS treatment. That guidance applies with particular force to fezolinetant, given the liver-monitoring requirement.

How much alcohol is too much?

Practically speaking:

• Zero alcohol in the first 12 weeks is the most liver-protective approach, covering the period of highest risk for drug-induced liver injury.
• After liver enzymes are confirmed normal at 3 months, no more than one standard drink on any given day is a reasonable ceiling, with several alcohol-free days each week.
• A standard drink in the United States is 14 grams of ethanol: 12 oz of regular beer, 5 oz of wine, or 1.5 oz of 80-proof spirits.
• Red wine contains additional compounds (histamine, tyramine) that are independent hot flash triggers in some women, separate from the alcohol effect.

Alcohol and sleep: the double hit

Alcohol fragments sleep architecture by suppressing REM sleep. Since hot flashes are significantly worse at night for most women taking Veozah, any sleep disruption amplifies the symptom load. Research in postmenopausal women found that even moderate alcohol consumption was associated with more frequent nocturnal vasomotor events. Veozah can help, but alcohol works against it in real time.

Foods That Trigger Hot Flashes Regardless of the Drug

Fezolinetant reduces the frequency and severity of hot flashes, but it does not eliminate every thermal trigger. These dietary triggers can still break through:

• Spicy food: capsaicin activates TRPV1 receptors, raising core body temperature acutely. Many women report breakthrough flushes within 20 minutes of eating very spicy meals, even on fezolinetant.
• Hot beverages: temperature alone, not caffeine, can trigger flushing. Letting coffee or tea cool to warm rather than hot makes a measurable difference for some women.
• High-glycemic meals: blood sugar spikes followed by rapid drops are associated with sympathetic nervous system activation, which can provoke flushing. A 2021 analysis in Menopause found that women following a high-glycemic diet had significantly worse VMS scores than those eating a lower-glycemic pattern.
• Large meals: a sudden increase in metabolic heat during digestion can provoke thermal discomfort. Eating smaller meals more frequently, rather than one or two large ones, may reduce this effect.

The Anti-Inflammatory Diet Framework for Women on Veozah

No clinical trial has tested a specific diet alongside fezolinetant. The framework below synthesizes three evidence bases: fezolinetant PK data, the WAVS (Women's and Veterans' Affairs Study) dietary trial in menopause, and general CYP1A2 nutrition pharmacology.

Prioritize foods that support liver health

Your liver is processing fezolinetant every day. Support it with:

• Cruciferous vegetables (moderate amounts): Broccoli, Brussels sprouts, and cauliflower support glucuronidation pathways. Moderate intake (one to two servings daily) is liver-supportive. Very large quantities daily may mildly induce CYP1A2, but this is unlikely to be clinically significant at normal dietary amounts.
• Coffee (one to two cups): Habitual, moderate coffee consumption is one of the most well-replicated dietary factors associated with lower rates of liver fibrosis and nonalcoholic fatty liver disease, per a meta-analysis in Alimentary Pharmacology and Therapeutics. Keep amounts consistent rather than variable.
• Omega-3 fatty acids: Fatty fish (salmon, mackerel, sardines), flaxseed, and walnuts reduce hepatic inflammation. Aim for two to three servings of fatty fish per week, consistent with AHA guidance.
• Limit added sugar and fructose: Fructose is metabolized almost entirely in the liver and is a driver of nonalcoholic fatty liver disease. With fezolinetant already requiring liver monitoring, minimizing ultra-processed foods and sugar-sweetened beverages is a sensible precaution.

Phytoestrogen foods: safe, but set expectations correctly

Soy isoflavones, flaxseed lignans, and red clover isoflavones are weakly estrogenic. Women often ask whether eating soy while on a non-hormonal therapy like Veozah is safe or helpful.

The short answer: soy food is safe and may offer a small, additive VMS benefit, but it does not interact with fezolinetant pharmacologically. A Cochrane review of phytoestrogens for VMS found modest reductions in hot flash frequency with isoflavone-rich diets, with a wide range of individual response. Soy does not block or amplify CYP1A2 meaningfully at dietary amounts.

Women with estrogen-receptor-positive breast cancer history should discuss soy intake with their oncologist regardless of fezolinetant use, as the evidence on soy safety in that population is nuanced.

Calcium and vitamin D: non-negotiable in menopause

Estrogen withdrawal accelerates bone loss. Since fezolinetant does not provide any bone protection, women in perimenopause and postmenopause taking Veozah still need to address skeletal health through diet and, where needed, supplementation.

ACOG recommends 1,200 mg of calcium daily for postmenopausal women, preferably from food sources (dairy, fortified plant milks, sardines with bones, leafy greens), with supplemental calcium split into doses of 500 mg or less for best absorption. Vitamin D should be maintained at 600 to 800 IU daily from dietary sources, with supplementation as needed to keep serum 25-OH vitamin D at or above 30 ng/mL.

Neither calcium nor vitamin D interacts with fezolinetant pharmacokinetics.

Magnesium: a practical, low-risk addition

Magnesium glycinate or magnesium citrate (200 to 400 mg at bedtime) is not FDA-approved for VMS, but research in the SSRI era of menopause care showed that magnesium oxide 400 mg twice daily reduced hot flash frequency by about 50 percent in a small pilot trial. As a dietary supplement, it has minimal interaction with CYP1A2, supports sleep quality, and is well tolerated. It is not a substitute for Veozah but may contribute to overall symptom management and sleep.

Meal Timing and the Once-Daily Dose

Fezolinetant can be taken with or without food according to the FDA label. A high-fat meal does not significantly alter fezolinetant AUC in pharmacokinetic studies, so you do not need to time it around meals for absorption reasons.

From a practical standpoint:

• Morning dosing with breakfast works well for most women because it anchors the dose to a consistent daily habit and avoids taking it on an empty stomach if you are prone to nausea.
• Evening dosing may suit women whose primary complaint is nocturnal sweating, although fezolinetant's half-life of roughly 10 hours means peak plasma levels occur 1 to 3 hours post-dose regardless of timing. There is no published head-to-head comparison of morning versus evening dosing for nocturnal VMS.
• Consistency matters more than timing. Take the tablet at the same time each day.

Supplements to Avoid or Use with Caution

| Supplement | Concern | Recommendation | |---|---|---| | High-dose curcumin (above 500 mg/day) | CYP1A2 inhibition, may raise fezolinetant levels | Dietary turmeric is fine; avoid high-dose capsules | | St. John's Wort | CYP1A2 inducer; reduces fezolinetant efficacy | Avoid | | High-dose green tea extract (EGCG) | CYP1A2 inhibitor at pharmacologic doses | Drinking 1-2 cups green tea daily is fine; avoid concentrated extracts | | Kava | Hepatotoxic; additive liver risk | Avoid entirely | | Black cohosh (high doses) | Possible hepatotoxicity signal (case reports) | Discuss with your clinician; unnecessary if Veozah is working | | Iron supplementation | No CYP interaction, but ferritin should be checked if fatigue is present | Use only if deficient | | Melatonin (0.5 to 3 mg) | No known CYP1A2 interaction; may improve sleep quality | Reasonable addition for sleep |

Dietary turmeric in cooking, drinking green tea, and eating culinary amounts of herbs are not a concern. The caution applies to concentrated supplement forms.

Pregnancy, Lactation, and Contraception

Fezolinetant is contraindicated in pregnancy. The drug's mechanism of action involves NK3 receptor antagonism, and NK3 signaling plays a role in reproductive hormone regulation. Animal reproductive toxicity studies showed adverse embryofetal effects at clinically relevant exposures, as described in the FDA prescribing information.

What this means by life stage:

• Postmenopausal women: No pregnancy risk. This is the intended population and the primary clinical indication.
• Perimenopausal women: Ovulation can still occur unpredictably even with irregular cycles. If you are in perimenopause and prescribed Veozah off-label (the FDA approval is for postmenopause, though VMS begins well before final menstrual period), you need reliable contraception while taking this drug.
• Women of reproductive age with surgical menopause: If menopause was induced by oophorectomy and pregnancy is not possible, contraception is not required. Confirm your reproductive status with your clinician before starting.

Lactation: There are no human data on fezolinetant transfer into breast milk. Given the lack of safety data and the drug's mechanism, fezolinetant should not be used while breastfeeding. The FDA label advises against use during lactation.

Fertility: Fezolinetant is not intended for use in reproductive-age women for fertility-related indications. NK3 signaling is involved in the GnRH pulse generator; theoretical concerns about menstrual cycle disruption exist, though fezolinetant in clinical trials did not cause clinically significant changes in LH or FSH in postmenopausal participants.

Who This Is Right For, and Who Should Be Cautious

Women most likely to benefit from Veozah plus nutrition optimization

• Postmenopausal women with moderate-to-severe VMS who cannot or choose not to use hormone therapy (survivors of hormone-sensitive cancers, women with contraindications to estrogen, or personal preference)
• Women with PCOS entering perimenopause who already have elevated liver enzyme risk from insulin resistance: these women need particularly careful liver monitoring and strict alcohol limitation
• Women with GSM alongside VMS: Veozah addresses only VMS, not genitourinary symptoms; local vaginal estrogen remains appropriate alongside fezolinetant and does not create a systemic estrogen concern
• Women managing surgical menopause symptoms, where VMS can be especially severe and hormone therapy is sometimes contraindicated

Women who should be cautious or discuss alternatives

• Women with pre-existing liver disease or elevated transaminases at baseline: the FDA label states that fezolinetant should not be initiated if ALT or AST is greater than 3 times the upper limit of normal
• Women taking strong CYP1A2 inhibitors by prescription (fluvoxamine, ciprofloxacin, enoxacin): fezolinetant is contraindicated with these agents per the prescribing information
• Women with heavy alcohol use disorder: liver risk is too high to use fezolinetant safely without first achieving sobriety and confirming normal liver function
• Women who are pregnant or breastfeeding: contraindicated (see above)

Living With Veozah Day to Day: A Practical Summary

WomanRx editorial board member Rachel Goldberg, MD, notes: "The women who get the most out of Veozah are the ones who treat the liver monitoring schedule seriously and cut alcohol right from day one. Diet will not make or break fezolinetant's mechanism, but it absolutely affects tolerability, breakthrough symptoms, and the safety data that comes back from your labs."

A practical daily checklist for women on Veozah:

1. Take your 45 mg tablet at the same time each day, with or without food.
2. Avoid alcohol entirely for the first 12 weeks. After confirmed normal liver enzymes at 3 months, limit to one drink maximum on any given day.
3. Avoid St. John's Wort and high-dose curcumin, EGCG, or kava supplements.
4. Keep caffeine intake consistent, not variable. One to two cups of coffee daily is reasonable.
5. Eat smaller, lower-glycemic meals to reduce thermal triggers throughout the day.
6. Let hot beverages cool before drinking them.
7. Meet calcium (1,200 mg daily from food and supplements combined) and vitamin D (600 to 800 IU) targets every day, since Veozah provides no bone protection.
8. Keep all three liver monitoring appointments: baseline, 3 months, and 6 months.
9. If you are perimenopausal and could become pregnant, use reliable contraception.
10. Report any right-upper-quadrant pain, jaundice, fatigue, or dark urine to your clinician immediately, as these are early signs of liver injury.

The SKYLIGHT 4 open-label extension study confirmed that fezolinetant's efficacy and liver safety profile remain stable through 52 weeks when monitoring protocols are followed. Women who completed that trial had a mean reduction in hot flash frequency of 63 percent from baseline. Following the nutrition and lifestyle principles in this article is how you stay in that majority.